Paras Healthcare IPO Details
Paras Healthcare IPO Summary
Paras Healthcare IPO opens for subscription on 21 Oct 2026 and closes on 23 Oct 2026.The IPO will be listed on NSE, BSE with the tentative listing date set for 28 Oct 2026.
Paras Healthcare IPO price band has been fixed at ₹660 – ₹693 per share. The face value is ₹1 per share with a lot size of 21.
Paras Healthcare IPO total issue size comprises 2,09,23,520 shares (aggregating up to ₹1450.00 Cr). This includes a fresh issue of 72,15,007 shares (aggregating up to ₹500.00 Cr). Offer for Sale consists of 1,37,08,513 shares (aggregating up to ₹950.00 Cr).
Paras Healthcare IPO carries a ₹13 (1.88%) GMP, reflecting investor sentiment.
Paras Healthcare IPO Lot Size :Retail Minimum is 1 lot (21 shares) amounting to ₹14,553. Retail Maximum is 13 lots (273 shares) amounting to ₹1,89,189. SHNI Minimum is 14 lots (294 shares) amounting to ₹2,03,742. SHNI Maximum is 68 lots (1,428 shares) amounting to ₹9,89,604. BHNI Minimum is 69 lots (1,449 shares) amounting to ₹10,04,157.
Paras Healthcare IPO Details
Paras Healthcare IPO Subscription
Paras Healthcare IPO Application Wise Breakup (Approx)
Paras Healthcare IPO Dates
- 21 Oct 2026Opening dateOpen
- 23 Oct 2026Closing dateClose
- 26 Oct 2026Allotment Date Allotment
- 27 Oct 2026Initiation of RefundsRefund
- 27 Oct 2026Credit of SharesCredit
- 28 Oct 2026Listing dateListing
Paras Healthcare IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 21 | ₹14,553 |
| Retail Maximum | 13 | 273 | ₹1,89,189 |
| SHNI Minimum | 14 | 294 | ₹2,03,742 |
| SHNI Maximum | 68 | 1428 | ₹9,89,604 |
| BHNI Minimum | 69 | 1449 | ₹10,04,157 |
Paras Healthcare IPO Reservation
Promoter Holding
Documents
Paras Healthcare IPO Valuations
Paras Healthcare Financial Information
| Period Ended | 30 Jun 2026 | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|---|
| Assets | 2,202.88 | 2,071.14 | 1,810.45 | 1,477.66 |
| Total Income | 478.75 | 1,628.78 | 1,314.21 | 1,151.02 |
| Profit After Tax | 49.68 | 43.83 | -57.98 | -15.33 |
| EBITDA | 113.48 | 335.58 | 156.46 | 154.41 |
| NET Worth | 444.96 | 394.94 | 280.49 | 338.51 |
| Reserves and Surplus | 434.86 | 384.84 | 270.73 | 328.75 |
| Total Borrowing | 1,429.49 | 1,393.86 | 1,232.12 | 923.92 |
| Amount in ₹ Crore | ||||
About Paras Healthcare IPO
Incorporated in1987, Paras Healthcare Limited is a leading clinical specialty-led hospital platform providing tertiary and quaternary healthcare services across North India, Bihar, and Jharkhand under the "Paras Health" brand. The company operates eight hospitals with an aggregate bed capacity of 2,211 beds across Gurugram, Panchkula, Patna, Darbhanga, Kanpur, Udaipur, Ranchi, and Srinagar as of June 30, 2026.
It specializes in cardiac sciences, oncology, neurosciences, gastro sciences, orthopedics & sports injury, and renal sciences (CONGOR specialties), which contributed 75.30% of revenue in Fiscal 2026.
Paras Healthcare has over 20 years of operating history and follows a balanced growth strategy through mature, emerging, and new hospitals. The company plans to expand its network with a 300-bed hospital in Gurugram and a 500-bed hospital in Ludhiana, increasing total capacity to 3,011 beds by March 2028.
As of March 31, 2026, it had 4,670 employees, including 1,084 doctors and 1,937 nurses.
Strength Of Paras Healthcare IPO
- One of the Largest Healthcare Providers in North India, Bihar and Jharkhand with a First Mover Advantage and a Well-Recognized Brand.
- Strong Focus on Tertiary and Quaternary Care with High Contribution from CONGOR Specialties.
- Capital-Efficient and Flexible Operating Model with Disciplined Expansion.
- Delivering High-Quality Clinical Care Through Renowned Clinicians, Supported with Modern Equipment.
- Digital Technology Enabling Clinical Effectiveness, Patient Experience and Operational Efficiencies.
- Doctor-Led Professional Management Team with Proven Execution Capabilities.
Risk Of Paras Healthcare IPO
- The Company has incurred losses during the three months period ended June 30, 2025 and Fiscals 2025 and 2024 of Rs. (10.24) million, Rs. (579.83) million and Rs. (153.31) million, respectively, on a consolidated basis. While the company were profitable in the three months period ended June 30, 2026 and Fiscal 2026, its cannot assure you that the company will continue to remain profitable in the future.
- The company's Subsidiaries, Paras Healthcare (Ranchi) Private Limited and Plus Medicare Hospitals Private Limited have collectively incurred a loss of Rs. (203.82) million, Rs. (520.89) million, Rs. (822.38) million and Rs. (872.69) million during the three months period ended June 30, 2025 and in Fiscals 2026, 2025 and 2024, respectively. Its cannot assure you that these Subsidiaries will turn profitable in the future.
- The company is highly dependent on doctors, nurses, other healthcare professionals and housekeeping and support staff for its operations. The company has experienced high attrition rates of 12.01%, 16.09%, 60.38%, 66.74% and 65.27% in the three months period ended June 30, 2026 and June 30, 2025 and in Fiscals 2026, 2025 and 2024, respectively. If the company is unable to reduce or manage the attrition rates of these professionals, its business, results of operations and financial condition may be adversely affected.
- Five of the company's eight hospitals are located in North India. In the three months period ended June 30, 2026 and June 30, 2025 and Fiscals 2026, 2025 and 2024, the revenue from these hospitals accounted for 68.07%, 66.89%, 66.07%, 68.40% and 67.33% of its revenue from operations, respectively. Any adverse developments affecting these hospitals or the regions in which they are located could affect the company's business, results of operations and financial condition.
- The name of one of the members of our Promoter Group, Harbaksh Singh Khangura appears in the CIBIL wilful defaulter database, and there is no guarantee that his name will be removed from the CIBIL defaulter database or that he will not be subject to any adverse proceedings or rulings in the future.
- We generate a significant portion of our revenue from the provision of cardiac sciences, oncology sciences, neuro sciences, gastro sciences, orthopedics and sports injury and renal sciences (collectively, "CONGOR") specialties, which contributed 74.35%, 75.30%, 74.70%, 71.92% and 72.34% of our revenue from operations in the three months period ended June 30, 2026 and June 30, 2025 and Fiscals 2026, 2025 and 2024, respectively. Any adverse developments in the demand for such services could adversely affect our business, results of operations and financial condition.
- The provision of healthcare services involves high costs such as employee benefit expenses, retainers and consultants fee and purchases of stock-in-trade, which together accounted for 66.13%, 64.40%, 65.08%, 63.69% and 66.95% of our total expenses in the three months period ended June 30, 2026 and June 30, 2025 and in Fiscals 2026, 2025 and 2024, respectively. If we fail to pass on these costs to patients, our business, results of operations and financial condition could be adversely affected.
- We conduct the operations of six of our eight hospitals on leased premises. We operate certain hospitals through revenue share arrangements and long-term leases, and we operate one hospital pursuant to a public-private partnership arrangement. Any adverse developments in our relationships with our lessors or counterparties, or our inability to renew such arrangements, could adversely affect our business, financial condition and results of operations.
- We have certain contingent liabilities that have been disclosed in our financial statements, which if they materialize, may adversely affect our results of operations, cash flows and financial condition. Our contingent liabilities, as of June 30, 2026, constituted 89.55% of our net worth.
- There are outstanding litigations against our Company, Subsidiaries, Promoter, Directors, Key Managerial Personnel and Senior Management, and there were certain regulatory and statutory proceedings initiated against our Promoter and Directors in the past. Any adverse decision in such proceedings, or similar instances in the future may render us or them liable for penalties, and may adversely affect our business, cash flows and reputation.
Objectives Paras Healthcare IPO
1. Prepayment or scheduled re-payment of a portion of certain outstanding borrowings availed by the Company.
2. Investment in our Subsidiaries, Paras Healthcare (Ranchi) Private Limited and Plus Medicare Hospitals Private Limited, in the form of debt or equity for repayment/prepayment of borrowings, in full or part, of such Subsidiaries.
3. General corporate purposes.
Company Contact Details
Paras Healthcare Ltd.
1 st Floor, Tower B, Paras Twin Towers,
Golf Course Road, Sector 54,
Gurugram – 122002, Haryana, India
Gurgaon, Haryana, 122002
Phone: +91 124 430 2163
Email: cs@parashospitals.com
Website: https://www.parashospitals.com/
Registrar Contact Details
Paras Healthcare FAQs
The Paras Healthcare IPO is a MAINBOARD public issue comprising 20923520 equity shares with a face value of ₹1 each, aggregating to a total issue size of ₹1450.00 Cr. The issue price has been fixed at ₹693 per equity share, and the minimum application size is 21 shares.
The IPO opens for subscription on 21 Oct 2026, and closes on 23 Oct 2026.
MUFG Intime India Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
As of now, the current GMP stands at ₹13 (1.88%).
Quick Links
Comments
